BERKELEY -
The poster will summarize data of the Bria-IMT Phase I/IIa clinical studies of Bria-IMT in combination with immune checkpoint inhibitors including pembrolizumab (KEYTRUDA; manufactured by
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.
BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT, BriaCell's lead candidate, in a Combination Study with immune checkpoint inhibitors such as the
BriaCell currently has a non-exclusive clinical trial collaboration with
BriaCell is also developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.
About Cancer Insight
Founded in 2014,
About SSO 2020 Annual Symposium
Over the years, the SSO 2020 annual symposium has become a meeting venue for practitioners around the world to discuss and offer expertise on a range of cancer related topics. The 2020 symposium sessions are comprehensive in the range of topics and the depth of expertise delivered. Management of Breast Cancer in Women Age 70+ will be a focused symposium section.
SSO 2020 will feature the debut of SSO HUB, a new and interactive experience that replaces the conventional exhibit hall. The HUB will feature five clinical zones - Breast/Endocrine, HPB, Melanoma/Sarcoma, Colorectal/Upper GI and Immuno-Oncology.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains 'forward-looking information' within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Tel: 1-888-485-6340
Email: farrah@BriaCell.com
(C) 2020 Electronic News Publishing, source